SCHEMBL23012202

SCHEMBL23012202

Cc1cc(CN(C(=O)OC(C)(C)C)c2cc(C)nc3c(-c4ccc5c(c4)c(C)nn5C)c(C)nn23)ccn1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 0.38
CRHR1 P34998 14/20 0.37
ALDH1A1 P00352 2/20 0.33
LMNA P02545 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29715036 1.00 PI4KB (0.38) PI4KBCRHR1ALDH1A1LMNAMEN1
SCHEMBL23012592 0.93 CRHR1 (0.36) PI4KBCRHR1ALDH1A1LMNATP53
SCHEMBL23747998 0.83 CRHR1 (0.32) PI4KBCRHR1
SCHEMBL29715016 0.83 CRHR1 (0.32) PI4KBCRHR1
SCHEMBL20533772 0.77 ALDH1A1 (0.35) PI4KBALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL29715033 0.76 SSTR4 (0.32) CRHR1
SCHEMBL16946635 0.75 CRHR1 (0.40) CRHR1ALDH1A1MEN1KMT2A
SCHEMBL20533660 0.73 PI4KB (0.35) PI4KBALDH1A1LMNAMEN1KMT2A
SCHEMBL23024624 0.73 PI4KB (0.62) PI4KBALDH1A1LMNAMEN1KMT2A
SCHEMBL29715021 0.73 PI4KB (0.62) PI4KBALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319696-B2 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections CUROVIR AB (SE) 2025-06-03 US disclosed
EP-4028131-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2023-11-22 EP disclosed
EP-3864017-B1 2,6-DIMETHYL-N-((PYRIDIN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDIN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS CUROVIR AB (SE) 2023-07-26 EP disclosed
EP-4028131-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2022-07-20 EP disclosed
US-20210340147-A1 2,6-DIMETHYL-N-((PYRIDlN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDlN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDlN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS CUROVIR AB (SE) 2021-11-04 US disclosed
EP-3864017-A1 2,6-DIMETHYL-N-((PYRIDIN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDIN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS CUROVIR AB (SE) 2021-08-18 EP disclosed
WO-2021032611-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319696-B2 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections ZC3HAV1, IFNAR1, ZYX PI4KB 821/4885CRHR1 1634/4885ALDH1A1 2692/4885
US-20210340147-A1 2,6-DIMETHYL-N-((PYRIDlN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDlN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDlN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS NSUN2, EIF2AK2, METTL16 PI4KB 482/4885CRHR1 4553/4885ALDH1A1 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.